After last week’s essay about this disease condition, it has become necessary to help readers understand the peculiar nature of the organ.

Between Friday, May 2, and Saturday, May 10, Washington National Opera will present five evening performances and one Sunday ...

Learn more about whether Merus N.V. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...

Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors, as shown in the phase 3 CABINET trial. The trial demonstrated a median PFS ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

City of Hope researchers demonstrate proof of concept for a novel targeted therapy for pancreatic cancer, exploiting transcription-replication conflicts to combat treatment resistance.